A federally approved heart drug shows significant effectiveness in interfering with SARS-CoV-2 entry into the human host cell, according to a new study by a research team from Texas A&M University and the Medical Branch. from the University of Texas (UTMB).
The drug bepridil, which goes by the brand name Vascor, is currently approved by the US Food and Drug Administration (FDA) to treat angina, a heart condition.
The team leaders are Wenshe College of Science Professor Ray Liu, Professor and Gradipore Chair in the Texas A&M Department of Chemistry, and Chien-Te Kent Tseng, Professor and Director of the SARS / MERS / COVID-Laboratory. 19 at UTMB. . Liu also holds joint teaching positions at Texas A&M schools of medicine, agriculture and life sciences.
“Currently, there is only one drug available, Remdesivir, to provide limited benefits to COVID-19 patients, and the virus can easily evade it,” Liu said. “Finding alternative medicines is imperative. Our team examined more than 30 FDA / European Medicines Agency approved drugs for their ability to inhibit the entry of SARS-COV-2 into human cells. The study found that bepridil offers the increased potential for treatment of COVID-19 As a result, we advocate that the use of bepridil be seriously considered in clinical trials related to SARS-CoV-2. “
The Texas A & M-UTMB study is now available on the peer review website. procedures of the National Academy of Sciences (PNAS) and its print release is scheduled for March 9.
The team, which includes six other researchers from Texas A&M and four from UTMB, now plans to advance their work to animal models with potential for clinical trials.
Follow the latest news on the coronavirus outbreak (COVID-19)
Erol C. Vatansever et al, Bepridil is potent against SARS-CoV-2 in vitro, procedures of the National Academy of Sciences (2021). DOI: 10.1073 / pnas.2012201118
Provided by Texas A&M University
Citation: Research team identifies potential drug to treat SARS-CoV-2 (February 22, 2021) obtained February 23, 2021 from https://medicalxpress.com/news/2021-02-team-potential- drug-sars-cov-.html
This document is subject to copyright. Apart from any fair dealing for private study or research purposes, no part may be reproduced without written permission. The content is provided for informational purposes only.